{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:18:48Z","timestamp":1790198328956,"version":"4.1.0"},"reference-count":68,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background\/Objectives: Psoriasis is currently treated with biologics targeting the IL-17A signaling, which plays a major role in immune response and keratinocyte hyperproliferation. These include inhibitors of IL-17A and\/or its heterodimer with IL-17F (Secukinumab, Ixekinumab and Bimekizumab) and the receptor IL17-RA (Brodalumab). Although these drugs are safe and highly effective, there is significant variability in response among patients. This can be partly attributed to the patients\u2019 genetic background, thus pointing to the need to identify pharmacogenetic markers for treatment response. Methods: The study involved 88 Greek patients who were treated with inhibitors of the IL-17A signaling for at least 6 months. Patients were classified as responders and non-responders according to the change in Psoriasis Area Severity Index. A total of 730,000 variants were genotyped and analyzed for association with the 3-month and 6-month responses to treatment. Results: The analysis identified 21 variants which were associated with the response, showing statistical significance after Bonferroni correction. These include variants located in protein coding genes (TP63, NRG1, SCN8A, TAF9, TMEM9, SMIM36, SYT14, BPIFC, SEZ6L2, PCARE), as well as intergenic and long non-coding RNA intronic variants. The functional significance of the variants was assessed using in silico analysis and for several variants, a link with immune processes was proposed. Notably, rs11649499 status, which was associated with complete clinical remission at 3 months, may influence key lipid mediators involved in psoriasis. Conclusions: This GWAS identified novel variants that could be utilized upon validation in larger populations as predictive markers regarding patient response to drugs targeting the IL-17A pathway.<\/jats:p>","DOI":"10.3390\/genes16101187","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:10:31Z","timestamp":1760343031000},"page":"1187","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Genome-Wide Association Study in Psoriasis Patients Reveals Variants Associated with Response to Treatment with Interleukin-17A Pathway Inhibitors"],"prefix":"10.3390","volume":"16","author":[{"given":"Dimitra","family":"Ioakeimidou","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Biotechnology, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efterpi","family":"Zafiriou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1842-5432","authenticated-orcid":false,"given":"Themistoklis","family":"Giannoulis","sequence":"additional","affiliation":[{"name":"Department of Animal Science, University of Thessaly, Gaiopolis, 41334 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kouvarou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Gerogianni","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-7902","authenticated-orcid":false,"given":"Dimitrios P.","family":"Bogdanos","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theologia","family":"Sarafidou","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Biotechnology, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6268-3394","authenticated-orcid":false,"given":"Kalliopi","family":"Liadaki","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Biotechnology, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis pathogenesis and treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Yi, R.C., Akbik, M., Smith, L.R., Klionsky, Y., and Feldman, S.R. (2025). Therapeutic Advancements in Psoriasis and Psoriatic Arthritis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041312"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/19420862.2015.1136761","article-title":"Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity","volume":"8","author":"Karle","year":"2016","journal-title":"mAbs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J. Inflamm. Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Adams, R., Maroof, A., Baker, T., Lawson, A.D.G., Oliver, R., Paveley, R., Rapecki, S., Shaw, S., Vajjah, P., and West, S. (2020). Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01894"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin- 17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.coi.2011.07.006","article-title":"Recent advances in the IL-17 cytokine family","volume":"23","author":"Gaffen","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","article-title":"IL-17 signaling: The Yin and the Yang","volume":"38","author":"Amatya","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Brembilla, N.C., Senra, L., and Boehncke, W.-H. (2018). The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01682"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/CCID.S462797","article-title":"The Role of Interleukin 23\/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials","volume":"17","author":"Potestio","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Galluzzo, M., Trovato, E., Talamonti, M., Caldarola, G., Di Nardo, L., Lazzeri, L., Mugheddu, C., Burlando, M., Balestri, R., and Bernardini, N. (2024). Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13133864"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00403-024-03594-w","article-title":"Long-term efficacy and safety of bimekizumab in real-world setting: A 52-week prospective study","volume":"317","author":"Potestio","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1007\/s12325-025-03258-9","article-title":"Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022\u20132023","volume":"42","author":"Puig","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jdv.19816","article-title":"Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)","volume":"38","author":"Rigopoulos","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Aggarwal, P., and Fleischer, A.B. (2024). IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175139"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","article-title":"Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis","volume":"84","author":"Thomas","year":"2024","journal-title":"Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wang, C.Y., Wang, C.W., Chen, C.B., Chen, W.T., Chang, Y.C., Hui, R.C., and Chung, W.H. (2023). Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087329"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1111\/jdv.14808","article-title":"Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: A retrospective case series","volume":"32","author":"Anzengruber","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjd.16705","article-title":"Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque- type psoriasis: SUPREME study","volume":"179","author":"Costanzo","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/jdv.15787","article-title":"Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: Results from a multicentre study of four European psoriasis cohorts","volume":"34","author":"Reek","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e15003","DOI":"10.1111\/exd.15003","article-title":"Association between several immune response-related genes and the effectiveness of biological treatments in patients with moderate-to- severe psoriasis","volume":"33","author":"Loras","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Morelli, M., Galluzzo, M., Madonna, S., Scarponi, C., Scaglione, G.L., Galluccio, T., Andreani, M., Pallotta, S., Girolomoni, G., and Bianchi, L. (2021). HLA-Cw6 and other HLAC alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. Expert. Opin. Biol. Ther., 21.","DOI":"10.1080\/14712598.2021.1862082"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2438803","DOI":"10.1080\/09546634.2024.2438803","article-title":"Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: An expert opinion of real-world evidence studies in Europe","volume":"36","year":"2025","journal-title":"J. Dermatolog Treat."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Liadaki, K., Zafiriou, E., Giannoulis, T., Alexouda, S., Chaidaki, K., Gidarokosta, P., Roussaki-Schulze, A.-V., Tsiogkas, S.G., Daponte, A., and Mamuris, Z. (2024). PDE4 Gene Family Variants Are Associated with Response to Apremilast Treatment in Psoriasis. Genes, 15.","DOI":"10.3390\/genes15030369"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ad.2014.10.001","article-title":"Treatment goals for psoriasis: Should PASI 90 become the standard of care?","volume":"106","author":"Torres","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kirsten, N., Rustenbach, S., von Kiedrowski, R., Sorbe, C., Reich, K., and Augustin, M. (2021). Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?. Life, 11.","DOI":"10.3390\/life11111151"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5395\/rde.2017.42.2.152","article-title":"Statistical notes for clinical researchers: Chi-squared test and Fisher\u2019s exact test","volume":"42","author":"Kim","year":"2017","journal-title":"Restor. Dent. Endod."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4028\/www.scientific.net\/AMM.611.115","article-title":"Methodology and Application of the Kruskal-Wallis Test","volume":"611","author":"Ostertag","year":"2014","journal-title":"Appl. Mech. Mater."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: A tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"D933","DOI":"10.1093\/nar\/gkac958","article-title":"Ensembl 2023","volume":"51","author":"Martin","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1101\/gr.9.8.677","article-title":"dbSNP-Database for Single Nucleotide Polymorphisms and Other Classes of Minor Genetic","volume":"9","author":"Sherry","year":"1999","journal-title":"Var. Genome Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gkr917","article-title":"HaploReg: A resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants","volume":"40","author":"Ward","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12325-022-02379-9","article-title":"Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting","volume":"40","author":"Lynde","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14712598.2018.1481503","article-title":"Secukinumab in moderate-to-severe plaque psoriasis: A multi-center, retrospective, real-life study up to 52 weeks observation","volume":"18","author":"Galluzzo","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1242\/dev.121723","article-title":"Lysophosphatidic acid signalling in development","volume":"142","author":"Sheng","year":"2015","journal-title":"Development"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41392-020-00379-1","article-title":"Lysophosphatidic acid mediates the pathogenesis of psoriasis by activating keratinocytes through LPAR5","volume":"6","author":"Lei","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gaire, B.P., Lee, C.H., Kim, W., Sapkota, A., Lee, D.Y., and Choi, J.W. (2020). Lysophosphatidic Acid Receptor 5 Contributes to Imiquimod-Induced Psoriasis-Like Lesions through NLRP3 Inflammasome Activation in Macrophages. Cells, 9.","DOI":"10.3390\/cells9081753"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kim, D., Kim, H.-J., Baek, J.-O., Roh, J.-Y., and Jun, H.-S. (2021). Lysophosphatidic Acid Mediates Imiquimod-Induced Psoriasis-like Symptoms by Promoting Keratinocyte Proliferation through LPAR1\/ROCK2\/PI3K\/AKT Signaling Pathway. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910777"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/jcmm.12952","article-title":"Pseudogenes regulate parental gene expression via ceRNA network","volume":"21","author":"An","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e15011","DOI":"10.1111\/exd.15011","article-title":"The impacts of biologic treatment on metabolic profiling in psoriasis","volume":"33","author":"Deng","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"120515","DOI":"10.1016\/j.cca.2025.120515","article-title":"The role of lipidomics in psoriasis","volume":"578","author":"Boboryko","year":"2026","journal-title":"Clin. Chim. Acta"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.it.2014.10.002","article-title":"NAIP inflammasomes give the NOD to bacterial ligands","volume":"35","author":"Maltez","year":"2014","journal-title":"Trends Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"eadq5091","DOI":"10.1126\/scitranslmed.adq5091","article-title":"Disrupting the RNA polymerase II transcription cycle through CDK7 inhibition ameliorates inflammatory arthritis","volume":"16","author":"Chen","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/ng.2756","article-title":"Systematic identification of trans eQTLs as putative drivers of known disease associations","volume":"45","author":"Westra","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1007\/s11033-011-1370-5","article-title":"Monocyte to macrophage differentiation-associated (MMD) positively regulates ERK and Akt activation and TNF-a and NO production in macrophages","volume":"39","author":"Liu","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4161\/cc.6.3.3753","article-title":"Control of keratinocyte proliferation and differentiation by p63","volume":"6","author":"Truong","year":"2007","journal-title":"Cell Cycle"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1346-8138.2005.tb00755.x","article-title":"The expression of p63 during epidermal remodeling in psoriasis","volume":"32","author":"Shen","year":"2005","journal-title":"J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.jid.5700010","article-title":"Dysregulation of TAp63 mRNA and protein levels in psoriasis","volume":"126","author":"Gu","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1111\/jcmm.15160","article-title":"Ozone therapy promotes the differentiation of basal keratinocytes via increasing Tp63-mediated transcription of KRT10 to improve psoriasis","volume":"24","author":"Gao","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Gentile, A., D\u2019Acquisto, F., and Leposavic, G. (2021). Editorial: The Bidirectional Communication Between Neurons and Immune Cells in the Development of Psychiatric, Neurological and Immune-Mediated Disorders. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.781151"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00109-010-0653-y","article-title":"In vivo and in vitro genetic evidence of involvement of neuregulin 1 in immune system dysregulation","volume":"88","author":"Marballi","year":"2010","journal-title":"J. Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12974-016-0703-7","article-title":"Regulation of inflammatory responses by neuregulin-1 in brain ischemia and microglial cells in vitro involves the NF-kappa B pathway","volume":"13","author":"Simmons","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"156439","DOI":"10.1016\/j.cyto.2023.156439","article-title":"Anti-inflammatory effects of neuregulin-1 in HaCaT keratinocytes and atopic dermatitis-like mice stimulated with Der p38","volume":"174","author":"Yun","year":"2024","journal-title":"Cytokine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"110797","DOI":"10.1016\/j.ygeno.2024.110797","article-title":"Identification and validation of CRLF1 and NRG1 as immune-related signatures in hypertrophic scar","volume":"116","author":"Yu","year":"2024","journal-title":"Genomics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.ajpath.2018.04.005","article-title":"IL-17 Promotes Scar Formation by Inducing Macrophage Infiltration","volume":"188","author":"Zhang","year":"2018","journal-title":"Am. J. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuron.2013.09.012","article-title":"Noncanonical Roles of Voltage-Gated Sodium Channels","volume":"80","author":"Black","year":"2013","journal-title":"Neuron"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pain.2008.03.016","article-title":"Voltage-gated sodium channel expression in rat and human epidermal keratinocytes: Evidence for a role in pain","volume":"139","author":"Zhao","year":"2008","journal-title":"Pain"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Alrashdi, B., Dawod, B., Tacke, S., Kuerten, S., C\u00f4t\u00e9, P.D., and Marshall, J.S. (2021). Mice Heterozygous for the Sodium Channel Scn8a (Nav1.6) Have Reduced Inflammatory Responses During EAE and Following LPS Challenge. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.533423"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhang, X., and He, Y. (2020). The Role of Nociceptive Neurons in the Pathogenesis of Psoriasis. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01984"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Dema, B., Pellefigues, C., Hasni, S., Gault, N., Jiang, C., Ricks, T.K., Bonelli, M.M., Scheffel, J., Sacr\u00e9, K., and Jablonski, M. (2014). Autoreactive IgE Is Prevalent in Systemic Lupus Erythematosus and Is Associated with Increased Disease Activity and Nephritis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090424"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00335-005-0127-7","article-title":"The human FK506-binding proteins: Characterization of human FKBP19","volume":"17","author":"Rulten","year":"2006","journal-title":"Mamm. Genome"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/iid3.65","article-title":"Overexpression of Fkbp11, a feature of lupus B cells, leads to B cell tolerance breakdown and initiates plasma cell differentiation","volume":"3","author":"Simoni","year":"2015","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_64","first-page":"4428","article-title":"FKBP11 protects intestinal epithelial cells against inflammation-induced apoptosis via the JNK-caspase pathway in Crohn\u2019s disease","volume":"18","author":"Wang","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.intimp.2018.07.036","article-title":"TMEM9 mediates IL-6 and IL-1\u03b2 secretion and is modulated by the Wnt pathway","volume":"63","author":"Wei","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41419-024-06669-8","article-title":"TMEM9 promotes lung adenocarcinoma progression via activating the MEK\/ERK\/STAT3 pathway to induce VEGF expression","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e697","DOI":"10.1002\/mgg3.697","article-title":"Novel heterozygous BPIFC variant in a Chinese pedigree with hereditary trichilemmal cysts","volume":"7","author":"Fu","year":"2019","journal-title":"Mol. Genet. Genomic Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhao, J., Jin, Q., and Zhuang, L. (2024). Transcriptomic Analyses and Experimental Validation Identified Immune-Related lncRNA-mRNA Pair MIR210HG- BPIFC Regulating the Progression of Hypertrophic Cardiomyopathy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052816"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/10\/1187\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:22:19Z","timestamp":1760343739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/10\/1187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":68,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["genes16101187"],"URL":"https:\/\/doi.org\/10.3390\/genes16101187","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]}}}